Abstract | AIM: METHODS: Serum estradiol (E2) content and bone 1-carboxyglutamic acid-containing protein (BGP) content were measured by radioimmunoassay. With undecalcified bone section and tetracycline intraperitoneal labeling, the bone static and dynamic data were studied in right femur samples. RESULTS:
After treatment with XW630 2.5 mg.kg-1, serum BGP content increased by 75.7% but there was no change in serum E2 content and uterus weight compared with OVX rats. Compared with OVX rats, the static data of trabecular bone volume/total tissue volume, trabecular bone volume/sponge bone volume, and mean trabecular plate density were enhanced after treatment with XW630 for 13 wk. The dynamic data of single-labeled surface, double-labeled surface, trabecular osteoid surface, and bone formation rate in tissue level in XW630 group were increased and osteoid maturation period was shortened. CONCLUSION:
XW630 enhanced bone activation frequency and increased trabecular connectivity, stability, and strength. XW630 stimulated bone formation and inhibited bone resorption with no effect on reproductive system.
|
Authors | L Sun, M C Qiu, L L Weng, H Zheng, J S Liu |
Journal | Acta pharmacologica Sinica
(Acta Pharmacol Sin)
Vol. 21
Issue 3
Pg. 200-4
(Mar 2000)
ISSN: 1671-4083 [Print] United States |
PMID | 11324415
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-(3-estrone-N-ethyl-piperazine-methyl)tetracycline
- Estrogens, Conjugated (USP)
- Piperazines
- Tetracyclines
- Estrone
- Estradiol
- Tetracycline
|
Topics |
- Animals
- Estradiol
(blood)
- Estrogens, Conjugated (USP)
(pharmacology)
- Estrone
(pharmacology)
- Female
- Femur
(drug effects)
- Humans
- Osteoporosis, Postmenopausal
(metabolism)
- Ovariectomy
- Piperazines
(pharmacology)
- Rats
- Rats, Wistar
- Tetracycline
(pharmacology)
- Tetracyclines
- Uterus
(drug effects)
|